... study, were not allowed. Treatment compliance Compliance was assessed by capsule count at visits 3, 4, and < /b> 5 and < /b> review of < /b> subject diary. Efficacy and < /b> Safety Variables Efficacy and < /b> safety ... study (visit 5). Blood samples (approximately 15 ml) were taken from subjects at day 30 and < /b> day 60 (visits 3 and < /b> 4) for the determination of < /b> ALT, AST, bilirubin, and < /b> albumin if the subjects had been ... Clinical conditions (body weight, body temperature, respiration rate, and < /b> pulse rate), and < /b> liver (bilirubin, GGT, and < /b> ALP) and < /b> kidney (BUN and < /b> creatinine) functions were not affected by UC-II treatment,...